子宫内膜癌PR、ER、PTEN、p53及Ki-67的表达情况及其与预后的相关性分析

目的 探讨子宫内膜癌孕激素受体(PR)、雌激素受体(ER)、磷酸酶与张力蛋白同源物(PTEN)、p53及Ki-67与临床病理特征和预后的相关性.方法 选取2008年7月-2009年1月收治的子宫内膜癌198例,收集患者临床、病理及术后随访等资料,对PR、ER、PTEN、p53及Ki-67与临床病理特征的关系和对预后的影响进行相关性分析.结果 ER阳性表达率在病理分型、FIGO分级、组织病理学分期、肌层浸润程度中比较差异有统计学意义(P＜0.05);不同病理分型、组织病理学分期中PR阳性表达率比较差异有统计学意义(P＜0.05);p53阳性表达率随组织病理分级越高表达水平越高,与病理分型有关(P＜0.05);Ki-67随着组织病理学分级越高表达水平越高(P＜0.05).FIGO分级Ⅲ～Ⅳ期、有淋巴结转移、PR阴性表达是影响子宫内膜癌患者预后生存的危险因素(P＜0.01).结论 PR表达水平与子宫内膜癌患者预后密切相关.

Expressions of PR,ER, PTEN,p53 and Ki-67 in Endometrial Cancer and Correlation Analysis with Prognosis

Objective To investigate correlations between progestins (PR),estrogen receptor (ER),phosphate and tension homology deleted on chromsomegen (PTEN),p53 and Ki-67 with clinicopathologic features and prognosis in patients with endometrial cancer.Methods Informations such as clinical,pathological and postoperative follow-up data of 198 patients with endometrial cancer admitted during July 2008 and January 2009 were selected,and correlations between PR,ER,PTEN,p53 and Ki-67 with clinicopathologic features were analyzed,and their effects on prognosis of endometrial cancer were also analyzed.Results The differences of ER positive expression rate in patients with different pathological type,federation international of gynecology and obstetrics (FIGO) staging,histopathologic staging and degree of myometrial infiltration were statistically significant (P ＜ 0.05).There were significant differences in positive expression rate of PR in patients with different pathological type and histopathologic stage (P ＜ 0.05).The positive expression rate of p53 was higher with increasing histopathologic stage,and the rate was correlated with the pathological type (P ＜ 0.05).Ki-67 level was higher with increasing histopathologic stage (P ＜ 0.05).FIGO Ⅲ-Ⅳ staging,lymphatic metastasis and PR negative expression were risk factors which affected prognosis of patients with endometrial cancer (P ＜ 0.01).Conclusion PR expression has close relation with prognosis of patients with endometrial cancer.